BC Week In Review | Jun 30, 2017
Clinical News

Xenetic begins Phase II of XBIO-101 in endometrial cancer

Xenetic Biosciences Inc. (NASDAQ:XBIO) began an open-label, U.S. Phase II trial to evaluate XBIO-101 (sodium cridanimod) plus progestin therapy in about 72 patients with recurrent or persistent endometrial cancer not amenable to surgical treatment or...
BC Week In Review | Dec 21, 2015
Company News

Pharmsynthez, Kevelt, Xenetic deal

Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5 million shares of Xenetic, valued at $93.7 million based on Xenetic close of $0.84 on Nov. 13, the last...
BC Week In Review | Jul 13, 2015
Financial News

Xenetic completes private placement of senior convertible notes

Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass.   Business: Drug delivery   Date completed: 2015-07-08   Type: Private placement of senior convertible notes   Raised: $3 million   Shares outstanding prior: 150 million   Investor: Pharmsynthez...
BC Week In Review | Dec 15, 2014
Clinical News

MyeloXen: Phase I/IIa ongoing

Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in 26 subjects. The first part enrolled 6 healthy volunteers, while the second and third parts enrolled 10 patients each...
BC Week In Review | May 26, 2014
Clinical News

PSA-Oxyntomodulin: Phase I data

A placebo-controlled, Russian Phase I trial in 12 healthy volunteers showed that single doses of 0.25, 0.75 and 1.5 mg/kg subcutaneous PSA-Oxyntomodulin were well tolerated. The trial was conducted by Pharmsynthez, which has exclusive rights...
BC Week In Review | Apr 14, 2014
Clinical News

PulmoXen: Phase I data

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the trial, plans to start...
BC Week In Review | Feb 3, 2014
Company News

Pharmsynthez, Rafarma Pharmaceuticals deal

Pharmsynthez and Rafarma have agreed to a production plan under which Rafarma's facilities will manufacture Pharmsynthez's products. Rafarma said the plan would double manufacturing capacity. The deal will close after Pharmsynthez's technical audit of Rafarma's...
BC Week In Review | Dec 9, 2013
Clinical News

PSA-Oxyntomodulin: Phase I started

Xenetic said Pharmsynthez began a placebo-controlled, Russian Phase I trial to evaluate 3 dose levels of PSA-Oxyntomodulin in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize the product outside of...
BC Week In Review | Dec 9, 2013
Clinical News

PulmoXen: Phase I started

Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units of PulmoXen in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize PulmoXen outside of...
BC Week In Review | May 6, 2013
Company News

Opko, Pharmsynthez deal

Opko acquired about a 10% stake in Russian pharmaceutical company Pharmsynthez. Opko said it made the investment alongside of Russian nanotechnology fund Rusnano, which invested about RUR820 million ($26.2 million). Opko said it and Rusnano...
Items per page:
1 - 10 of 23
BC Week In Review | Jun 30, 2017
Clinical News

Xenetic begins Phase II of XBIO-101 in endometrial cancer

Xenetic Biosciences Inc. (NASDAQ:XBIO) began an open-label, U.S. Phase II trial to evaluate XBIO-101 (sodium cridanimod) plus progestin therapy in about 72 patients with recurrent or persistent endometrial cancer not amenable to surgical treatment or...
BC Week In Review | Dec 21, 2015
Company News

Pharmsynthez, Kevelt, Xenetic deal

Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5 million shares of Xenetic, valued at $93.7 million based on Xenetic close of $0.84 on Nov. 13, the last...
BC Week In Review | Jul 13, 2015
Financial News

Xenetic completes private placement of senior convertible notes

Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass.   Business: Drug delivery   Date completed: 2015-07-08   Type: Private placement of senior convertible notes   Raised: $3 million   Shares outstanding prior: 150 million   Investor: Pharmsynthez...
BC Week In Review | Dec 15, 2014
Clinical News

MyeloXen: Phase I/IIa ongoing

Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in 26 subjects. The first part enrolled 6 healthy volunteers, while the second and third parts enrolled 10 patients each...
BC Week In Review | May 26, 2014
Clinical News

PSA-Oxyntomodulin: Phase I data

A placebo-controlled, Russian Phase I trial in 12 healthy volunteers showed that single doses of 0.25, 0.75 and 1.5 mg/kg subcutaneous PSA-Oxyntomodulin were well tolerated. The trial was conducted by Pharmsynthez, which has exclusive rights...
BC Week In Review | Apr 14, 2014
Clinical News

PulmoXen: Phase I data

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the trial, plans to start...
BC Week In Review | Feb 3, 2014
Company News

Pharmsynthez, Rafarma Pharmaceuticals deal

Pharmsynthez and Rafarma have agreed to a production plan under which Rafarma's facilities will manufacture Pharmsynthez's products. Rafarma said the plan would double manufacturing capacity. The deal will close after Pharmsynthez's technical audit of Rafarma's...
BC Week In Review | Dec 9, 2013
Clinical News

PSA-Oxyntomodulin: Phase I started

Xenetic said Pharmsynthez began a placebo-controlled, Russian Phase I trial to evaluate 3 dose levels of PSA-Oxyntomodulin in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize the product outside of...
BC Week In Review | Dec 9, 2013
Clinical News

PulmoXen: Phase I started

Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units of PulmoXen in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize PulmoXen outside of...
BC Week In Review | May 6, 2013
Company News

Opko, Pharmsynthez deal

Opko acquired about a 10% stake in Russian pharmaceutical company Pharmsynthez. Opko said it made the investment alongside of Russian nanotechnology fund Rusnano, which invested about RUR820 million ($26.2 million). Opko said it and Rusnano...
Items per page:
1 - 10 of 23